COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Guidance for cancer researchers:

Get the latest public health information from CDC:

Get the latest research information from NIH:

Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer

This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.

Research Base: University of Rochester NCORP Research Base
NCT ID: NCT03186638
NCI Protocol Number: URCC-16092
Status: Recruiting

For more information see



Cognitive Impairment, Malignant Neoplasm

Trial Type

Comparative Effectiveness Research

See a list of participating sites on